Astera Labs (ALAB) Stock Plunges 14% Amid Heavy Insider Selling Activity
Astera Labs (ALAB) stock plummeted 14% Monday as insiders sold millions, geopolitical risks escalated, and Nasdaq-100 rebalancing created headwinds. The post Astera Labs (ALAB) Stock Plunges 14% Amid…
Read the full articleYou might also wanna read
Astera Labs Fell 12% Monday. Here’s Where ALAB Stock Could Head in 2026
Astera Labs stock fell 12% Monday as a semiconductor selloff tested its premium valuation. Here’s why the Scorpio switch ramp could determin
Astera Labs Stock Fell Nearly 12% in a Single Day. Here’s Where the Stock Could Go in 2026
Astera Labs stock dropped nearly 12% in a single session, dragged down by an AI-sector selloff rather than any news of its own. With no comp
An Astera Labs Insider Sold at $458, but the 93% Revenue Growth Is the Real Story
Manuel Alba's sale follows a 386% one-year surge in Astera Labs shares. The semiconductor company now trades at a $69.7 billion market cap.
Astera Labs Blockbuster IPO Reveals Strong AI Market
Astera's IPO dazzled the Street. The company is betting on a big market opportunity but may have to grow big in a short timeframe
Thursday’s Stock Market Winners and Losers: Alnylam Pharmaceuticals (ALNY) Jumps 18% as AstraZeneca (AZN) Plunges
Alnylam Pharmaceuticals (ALNY) surges 18% in premarket trading while AstraZeneca (AZN) drops 9% on failed trial. See Thursday's biggest stoc
AstraZeneca Plunges After New Heart Disease Drug Fails Trial
AstraZeneca’s shares fell as much as 10.6% in London, which is its largest intraday plummet since 2017, per Bloomberg. The post AstraZeneca
Comments
Sign in to join the conversation.
No comments yet. Be the first.